(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005455 A2

(51) International Patent Classification[7]: C07K

(21) International Application Number:
PCT/US2004/021099

(22) International Filing Date: 30 June 2004 (30.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/610,840 30 June 2003 (30.06.2003) US

(71) Applicant *(for all designated States except US)*: **SAVIENT PHARMACEUTICALS, INC.** [US/US]; One Tower Center Boulevard, East Brunswick, NJ 08816 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LEVANON, Avigdor** [IL/IL]; 8 Mollivar Street, Revohot (IL). **VOGEL, Tikva** [IL/IL]; 4 Kosovar Street, Rehovot (IL). **PLAKSIN, Daniel** [IL/IL]; 12 Paldi Street, Rehovot (IL). **PERETZ, Tuvia** [IL/IL]; 5 Pereg Street, Hod Hasharon (IL). **AMIT, Boaz** [IL/IL]; 49 Zahal Street, Kiron (IL). **COOPERMAN, Lena** [IL/IL]; 19/7 Horovitz Street, Rishon Lezion (IL). **HAGAY, Yocheved** [IL/IL]; 23 Rupin Street, Rehovot (IL). **SZANTON, Esther** [IL/IL]; 16 Smilansky Street, Rehovot (IL). **KANFI, Yariv** [IL/IL]; 6/14 Zichron Yaakov Street, Pethch Tikva (IL). **BEN-LEVY, Rachel** [IL/IL]; 25 Benei Street, Reem (IL).

(74) Agents: **SOMERVILLE, Deborah, A.** et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/005455 A2

(54) Title: SPECIFIC HUMAN ANTIBODIES

(57) Abstract: The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the present antibodies.